Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Decentralized microfluidic in vitro diagnostic patch for pandemic control

Project description

Revolutionary in vitro diagnostic technology for pandemic control

In vitro diagnostic technology holds promise to revolutionise healthcare by providing a crucial tool in combating pandemics and viral outbreaks. Unfortunately, despite its potentially faster and more cost-effective diagnosis, it still remains confined to labs, even during the recent pandemic, and thus not in the hands of end-users. Lab-on-a-chip technologies were considered a promising alternative, but their high cost, complexity and other factors have meant they have failed to fill the gap. The EU-funded DECIPHER project will address these challenges by developing a microfluidic-based patch featuring biofluid sampling through hollow microneedles and immediate self-powered sample analysis with a quantitative readout of the result. It will demonstrate the solution's efficacy against Ebola and Lassa viruses and as a model system for other dangerous pandemic threats.

Objective

In vitro diagnostic (IVD) technologies have revolutionized healthcare, yet remain confined to the laboratories. This traditional approach massively failed to manage viral outbreak during the COVID-19 pandemic because it lacked quick and cost-effective diagnosis. Moreover, an urgent need was evident for bringing quantitative lab-quality diagnosis to the hands of end users (i.e. point-of-care, POC). Despite high expectations from Lab-on-Chip technologies, they failed so far to disrupt the IVD market due to their complexity, high cost, off-chip sample preparation, poor scalability, to mention a few. The DECIPHER consortium aims to revolutionize the POC IVD field by developing innovative microfluidic-based DECIPHER patch capable of both biofluids (self-)sampling via hollow microneedles (HMNs) and immediate analysis of this sample on the very same patch in a completely self-powered manner, producing quantitative result to be read out with a re-purposed glucose meter. Ebola and Lassa viruses are selected as relevant model systems because they are highly contagious with human-to-human transmission, high mortality rate and no vaccine/treatment available, thus having meaningful potential for new pandemic threats. To offer such a genuine sample-to-result quantitative POC solution, the DECIPHER value chain, from lab to market, will cover: (1) investigation of high-throughput manufacturing processes with (2) novel polymers, innovations in the fields of (3) microfluidics, (4) HMNs and (5) quantitative molecular bioassays, (6) DECIPHER patch analytical and clinical validation (both retrospective and prospective), as well as (7) AI-based models, (8) socio-economic/systems analysis and (9) life cycle assessment of DECIPHER patch. This true interdisciplinarity will be represented by highly experienced DECIPHER consortium with partners from 3 universities, 5 research institutes, 1 SME, 1 large company and 1 non-governmental organization from 6 countries.

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-IA - HORIZON Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2023-TOOL-05

See all projects funded under this call

Coordinator

KATHOLIEKE UNIVERSITEIT LEUVEN
Net EU contribution
€ 2 445 327,50
Address
OUDE MARKT 13
3000 Leuven
Belgium
Region
Vlaams Gewest Prov. Vlaams-Brabant Arr. Leuven
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 445 327,50

Participants (9)

Partners (1)